For the quarter ended December 2025, Penumbra (PEN) reported revenue of $385.39 million, up 22.1% over the same period last year. EPS came in at $1.18, compared to $0.97 in the year-ago quarter.
The reported revenue represents a surprise of +6.74% over the Zacks Consensus Estimate of $361.04 million. With the consensus EPS estimate being $1.12, the EPS surprise was +5.36%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Penumbra performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:- Geographic Revenue- United States: $299.05 million compared to the $289.07 million average estimate based on three analysts. The reported number represents a change of +20.6% year over year.
- Geographic Revenue- International: $86.33 million compared to the $73.9 million average estimate based on three analysts. The reported number represents a change of +27.7% year over year.
- Revenue- Embolization and Access - International: $34.7 million versus $31.06 million estimated by three analysts on average.
- Revenue- Thrombectomy - International: $51.63 million compared to the $42.84 million average estimate based on three analysts.
- Revenue- Embolization and Access - United States: $95.99 million compared to the $80.72 million average estimate based on three analysts.
- Revenue- Thrombectomy - United States: $203.07 million versus $208.34 million estimated by three analysts on average.
- Revenue- Embolization and Access: $130.69 million versus the three-analyst average estimate of $111.78 million. The reported number represents a year-over-year change of +37%.
- Revenue- Thrombectomy: $254.7 million compared to the $251.19 million average estimate based on three analysts. The reported number represents a change of +15.7% year over year.
View all Key Company Metrics for Penumbra here>>>
Shares of Penumbra have returned -5.5% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks Names #1 Semiconductor Stock
This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.
With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.
See This Stock Now for Free >>Penumbra, Inc. (PEN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
